Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
NCT07562659Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07562659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562659.